Are pancreatic neuroendocrine tumors different from other pancreatic cancer?

Yes. The differences are big enough that treating them as one disease will mislead you. Pancreatic neuroendocrine tumors start in different cells. They are treated with different drugs. And they carry a much better outlook.

Two organs sharing one name

The pancreas does two unrelated jobs. Most of it is exocrine tissue. That tissue makes digestive enzymes and pipes them into ducts headed for the gut. Scattered through it are small clusters called islet cells. They make hormones and send them straight into the blood.

Nearly all pancreatic cancer comes from the exocrine side. NCI's summary for clinicians says these tumors "originate in islet cells." It also notes that "they account for less than 2% of pancreatic malignancies."

Less than 2 percent. That single figure explains most of the confusion these patients run into.

Why that matters the moment you start reading

Almost everything written about pancreatic cancer, including survival statistics, describes the exocrine type. NCI states that pancreatic neuroendocrine tumors carry a "better prognosis than the more common pancreatic exocrine tumors."

So if this is your diagnosis, the grim numbers that come up in a search are not your numbers. This is the most useful thing on this page. Check which disease a statistic is describing before you let it land.

Functional and nonfunctional

NCI notes that "islet tumors may either be functional (produce one or more active hormones) or nonfunctional." That split shapes how the tumor shows up.

Functional tumors are named for what they make. An insulinoma makes insulin. A gastrinoma makes gastrin. NCI also lists glucagonoma, VIPoma, and somatostatinoma. The hormone acts all over the body. So these tumors can announce themselves through symptoms that seem to have nothing to do with the pancreas. Sometimes that happens while the tumor is still small.

Nonfunctional tumors make no active hormone. They are quieter, so they tend to be found later. Often it is by chance, on a scan done for something else.

Different drugs entirely

The treatment lists barely overlap with those for exocrine pancreatic cancer. NCI names somatostatin analogues, everolimus, and sunitinib. It also names radiolabeled somatostatin analogues, a treatment usually called PRRT. PRRT attaches a radioactive particle to a molecule that seeks out these tumor cells.

This is why an accurate pathology report is not a formality. It selects a completely different set of options.

The family question

Some of these tumors are inherited. NCI states that "some occur as part of the autosomal dominant multiple endocrine neoplasia type 1 (MEN1) inherited syndrome." Autosomal dominant means one copy of the altered gene is enough. It can come from either parent. Each child of a carrier has a one in two chance of inheriting it.

MEN1 also involves tumors in other hormone glands. So a diagnosis can matter for relatives who feel entirely well.

If you or a family member has a pancreatic neuroendocrine tumor, two questions are worth asking directly. Is it functional or nonfunctional? And has anyone considered whether MEN1 testing is appropriate here? Both change what happens next. Neither is always raised without prompting.